Clinical trials: Head and Neck Tumours
Squamous Cell Carcinoma of Larynx
Study of a Pembrolizumab-based Organ Preservation Strategy for Locally Advanced Larynx Cancers
This a prospective, single-arm, multi-institutional, open label, phase 2 trial evaluating the effects of induction chemo-immunotherapy, followed by radioimmunotherapy, followed by consolidation immunotherapy in patients with…
- Trial name
- SMART-KEY (NCT04943445)
- Testing
- carboplatin AUC of 6, paclitaxel 175 mg/m2, and pembrolizumab 200 mg, i.v. on day 1, every 21 days for 3 cycles, Concurrent radio-immunotherapy: radiation therapy given concurrently with pembrolizumab 200 mg i.v. on day 1, every 21 days for 3 cycles., Consolidation immunotherapy: pembrolizumab 200 mg i.v. on day 1, every 21 days for 11 doses.
- Where
- 9 sites in Brazil
- Volunteers
- 43 people
- Sponsor
- Latin American Cooperative Oncology Group
Clear Cell Renal Cell Carcinoma, Cervical Carcinoma
A Safety and Efficacy Study Evaluating CTX131 in Adult Subjects With Relapsed or Refractory Solid Tumors
This is an open-label, multicenter, Phase 1/2 study evaluating the safety and efficacy of CTX131™ in subjects with relapsed or refractory solid tumors.
- Conditions
- Clear Cell Renal Cell Carcinoma, Cervical Carcinoma, Esophageal Carcinoma, Pancreatic Adenocarcinoma
- Trial name
- NCT05795595
- Testing
- CTX131
- Where
- 7 sites in United States
- Volunteers
- 19 people
- Sponsor
- CRISPR Therapeutics AG
Squamous Cell Carcinoma, Oral Cavity Squamous Cell Carcinoma
Phase 2 Trial of Neoadjuvant and Adjuvant Tiragolumab Plus Atezolizumab in Patients With Newly Diagnosed PD-L1 CPS Positive Resectable Stage 3-4 Oral Cavity Squamous Cell Carcinoma (OCSCC).
To learn if treatment with tiragolumab and atezolizumab before and after standard of care surgery and chemoradiation (radiation therapy with or without cisplatin/carboplatin) can help to control OCSCC that is PD-L1 CPS positive.
- Trial name
- NCT05681039
- Testing
- Tiragolumab, Atezolizumab, Standard of Care
- Where
- United States
- Volunteers
- 29 people
- Sponsor
- M.D. Anderson Cancer Center
Cancer
Excision Limits of Oral Cavity Tumor by Narrow Band Imaging
This study evaluates the feasibility of the NBI technique in the detection of early cancer lesions.
- Trial name
- NBI-CAB (NCT01198119)
- Testing
- Location of the suspected lesions, Biopsy, Lesion excision/Surgery
- Where
- France
- Volunteers
- 23 people
- Sponsor
- Centre Oscar Lambret
Oral Cancer
Therapeutic Efficacy of Quercetin Versus Its Encapsulated Nanoparticle on Tongue Squamous Cell Carcinoma Cell Line
Squamous cell carcinoma (SCC) is the most common oral cavity carcinoma. Conventional therapeutic modalities for oral malignancy include surgery, radiotherapy and chemotherapy alone or in combinations.The major obstacle of using…
- Trial name
- NCT05456022
- Testing
- Quercetin 3,3',4',5,6-Pentahydroxyflavone, 2-(3,4-Dihydroxyphenyl)-3,5,7-trihydroxy-4H-1-benzopyran-4-one, Quercetin-encapsulated PLGA-PEG nanoparticles (Nano-QUT), Doxorubicin chemotherapeutic drug as a positive control
- Where
- Egypt
- Volunteers
- 1,000,000 people
- Sponsor
- Cairo University
Head and Neck Squamous Cell Carcinoma, Head and Neck Cancer
SOTO: Treatment Sensitivity of Organoids to Predict Treatment Outcome
In this study, we aim to assess whether Patient Derived Organoids can be used to predict treatment sensitivity in HNSCC patients.
- Trial name
- NCT05400239
- Where
- United Kingdom
- Volunteers
- 60 people
- Sponsor
- Guy's and St Thomas' NHS Foundation Trust
Nasopharyngeal Cancer
Whole-Body 18F-FDG PET in Induction Chemotherapeutic Response for Advanced NPC Patients
18F-FDG PET, a whole-body imaging technology based on glucose metabolism, can effectively detect subclinical and clinical therapeutic responses at stages that are earlier than those detected by conventional approaches.
- Trial name
- NCT00304694
- Where
- Taiwan
- Volunteers
- 50 people
- Sponsor
- National Taiwan University Hospital
Gastro-esophageal Junction (GEJ) Cancer, Esophagus Cancer
Perioperative FLOT(D) With Personalized Ultrafractionated Stereotactic Adaptive Radiotherapy (PULSAR) in Esophageal Cancer
The goal of this clinical trial is to learn the safety of the addition of PULSAR radiation to standard of care chemotherapy and immunotherapy in people with esophageal and gastroesophageal junction cancer and to determine the…
- Trial name
- NCT07700420
- Testing
- PULSAR- Personalized Ultra-fractionated Stereotactic Ablative Radiotherapy, FLOT (Fluorouracil+Leucovorin+Oxaliplatin+Docetaxel)(D)
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- University of Texas Southwestern Medical Center
Pancreatic Cancer, Metastatic Castration-resistant Prostate Cancer
Study of NGM120 in Subjects With Advanced Solid Tumors, Pancreatic Cancer, and Prostate Cancer Using Combination Therapy
Study of NGM120 in subjects with advanced solid tumors and pancreatic cancer (Part 1 and 2) and metastatic castration resistant prostate cancer (Part 3).
- Conditions
- Pancreatic Cancer, Metastatic Castration-resistant Prostate Cancer, Bladder Cancer, Melanoma
- Trial name
- NCT04068896
- Testing
- NGM120 30mg, NGM120 100mg, NGM120 30mg with Gemcitabine and Abraxane
- Where
- 20 sites in United States
- Volunteers
- 89 people
- Sponsor
- NGM Biopharmaceuticals, Inc
Laryngeal Squamous Cell Carcinoma
IMP3 and PCNA Expression in Laryngeal Squamous Cell Carcinoma in Sohag Governorate
Laryngeal cancer is responsible for 2-5% of all new cancer cases worldwide. Squamous cell carcinoma of the larynx (LSCC) is the most common malignant tumor of the larynx, accounting for 85-90% of all laryngeal malignancies.
- Trial name
- IMP3PCNA (NCT05293327)
- Where
- Egypt
- Volunteers
- 70 people
- Sponsor
- Sohag University
Esophageal Squamous Cell Carcinoma
Concurrent Chemoradiotherapy After Endoscopic Resection for Stage I Esophageal Carcinoma
This is a prospective single-arm study of endoscopic resection (ER) following concurrent chemoradiotherapy for stage I esophageal squamous cell carcinoma, to find if the treatment combination is useful by assessing its safety and…
- Trial name
- NCT04275986
- Testing
- Intensity modulated radiotherapy (IMRT), Chemotherapy
- Where
- China
- Volunteers
- 56 people
- Sponsor
- Chinese Academy of Medical Sciences
Head and Neck Cancer
S0216, Combination Chemotherapy and RT in Treating Patients With Stage III or Stage IV Head and Neck Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Radiation therapy uses high-energy x-rays to damage tumor cells.
- Trial name
- NCT00054054
- Testing
- cisplatin, docetaxel, fluorouracil
- Where
- 95 sites in United States, Canada
- Sponsor
- SWOG Cancer Research Network
Oral Squamous Cell Carcinoma (OSCC), Diagnosis
Trop2-targeting NIR-II Molecular Probe for Precision Diagnosis of Oral Cancer
Given the morphological and clinical similarities between certain oral malignant neoplasms and benign conditions such as oral ulcerations or inflammatory lesions, the potential for misdiagnosis is significant.
- Trial name
- NCT07794813
- Testing
- TTP-ICG incubation solution
- Where
- China
- Volunteers
- 40 people
- Sponsor
- Yunnan Cancer Hospital
Lymphedema of Face, Secondary Lymphedema
Complete Decongestive Therapy on Head and Neck Lymphedema
This will be a prospective, randomized controlled study of ~60 adult patients who have undergone a laryngectomy, neck dissection, maxillectomy or mandibulectomy surgical procedure for the treatment of head and neck cancer at Our…
- Trial name
- NCT04045860
- Testing
- Complete Decongestive Therapy, Observation
- Where
- United States
- Volunteers
- 38 people
- Sponsor
- Our Lady of the Lake Hospital
Solid Tumors
Dose Escalation of RMC-4630 Monotherapy in Relapsed/Refractory Solid Tumors
The purpose of this study is to evaluate the safety, tolerability, pharmacokinetic (PK), and pharmacodynamic (PD) profiles of escalating doses of RMC-4630 monotherapy in adult participants with relapsed/refractory solid tumors…
- Trial name
- NCT03634982
- Testing
- RMC-4630
- Where
- 12 sites in United States
- Volunteers
- 133 people
- Sponsor
- Revolution Medicines, Inc.
Oropharyngeal Cancer, Palate Free Flap Reconstruction
Functional Results of Soft Palate Free Flap Reconstruction
The oropharynx is a complex anatomical structure necessary for nasal breathing, swallowing and phonation. The removal of oropharyngeal cancers can lead to sequelae, particularly in the case of resections affecting the soft…
- Trial name
- RECaVoLL (NCT03890783)
- Testing
- Evaluation of phonation quality, Evaluation of swallowing quality, global quality of life questionnaire
- Where
- France
- Volunteers
- 29 people
- Sponsor
- Hospices Civils de Lyon
Esophageal Neoplasm, Head and Neck Neoplasm
The Effects of Upper Airway and Digestive Tract Tumors on the Immune System
The goal of this study is to learn how tumors of the upper airway and digestive passages (tongue, throat, mouth, and voicebox) affect the body's immune defenses and energy storage.
- Conditions
- Esophageal Neoplasm, Head and Neck Neoplasm, Laryngeal Neoplasm, Papilloma
- Trial name
- NCT00001603
- Where
- United States
- Volunteers
- 93 people, healthy volunteers welcome
- Sponsor
- National Institute on Deafness and Other Communication Disorders (NIDCD)
Esophageal Squamous Cell Carcinoma (ESCC)
Phase II Study of Induction Chemoimmunotherapy Followed by Radiotherapy and Organ Preservation in Resectable ESCC
This multicenter, prospective Phase II study investigates a response-adapted organ-preservation strategy in patients with resectable esophageal squamous cell carcinoma (ESCC).
- Trial name
- SCOPE (NCT07711470)
- Testing
- Sugemalimab and Chemotherapy, Nab-paclitaxel, Cisplatin
- Where
- China
- Volunteers
- 140 people
- Sponsor
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Head and Neck Cancer, Cervical Cancer
A Study of ILB2109 and Toripalimab in Patients With Advanced Solid Malignancies
This is a multicenter, open-label, phase Ib/IIa study. The first part of the study will evaluate the safety, tolerability and preliminary efficacy of ILB2109 and Toripalimab in patients with locally advanced or metastatic solid…
- Conditions
- Head and Neck Cancer, Cervical Cancer, Endometrial Cancer, Triple Negative Breast Cancer
- Trial name
- NCT05955105
- Testing
- ILB-2109, Toripalimab
- Where
- China
- Volunteers
- 200 people
- Sponsor
- Innolake Biopharm
Non-Small Cell Lung Cancer (NSCLC), Colorectal Cancer
Study of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Participants With Advanced KRAS G12C Mutant Solid Tumors
This study is to evaluate the safety, tolerability, and PK profiles of Elironrasib and Daraxonrasib as monotherapies and combination therapy in patients with KRAS G12C-mutated solid tumors.
- Conditions
- Non-Small Cell Lung Cancer (NSCLC), Colorectal Cancer, Pancreatic Ductal Adenocarcinoma
- Trial name
- NCT06128551
- Testing
- Elironrasib, Daraxonrasib
- Where
- 56 sites in United States, France and 5 more
- Volunteers
- 534 people
- Sponsor
- Revolution Medicines, Inc.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.